BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 36841437)

  • 41. Clinicopathologic and Immunophenotypic Characterization of 25 Cases of Acinic Cell Carcinoma with High-Grade Transformation.
    Thompson LD; Aslam MN; Stall JN; Udager AM; Chiosea S; McHugh JB
    Head Neck Pathol; 2016 Jun; 10(2):152-60. PubMed ID: 26245749
    [TBL] [Abstract][Full Text] [Related]  

  • 42.
    Nayyar N; White MD; Gill CM; Lastrapes M; Bertalan M; Kaplan A; D'Andrea MR; Bihun I; Kaneb A; Dietrich J; Ferry JA; Martinez-Lage M; Giobbie-Hurder A; Borger DR; Rodriguez FJ; Frosch MP; Batchelor E; Hoang K; Kuter B; Fortin S; Holdhoff M; Cahill DP; Carter S; Brastianos PK; Batchelor TT
    Blood Adv; 2019 Feb; 3(3):375-383. PubMed ID: 30723112
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Genetic analysis of microglandular adenosis and acinic cell carcinomas of the breast provides evidence for the existence of a low-grade triple-negative breast neoplasia family.
    Geyer FC; Berman SH; Marchiò C; Burke KA; Guerini-Rocco E; Piscuoglio S; Ng CK; Pareja F; Wen HY; Hodi Z; Schnitt SJ; Rakha EA; Ellis IO; Norton L; Weigelt B; Reis-Filho JS
    Mod Pathol; 2017 Jan; 30(1):69-84. PubMed ID: 27713419
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The repertoire of somatic genetic alterations of acinic cell carcinomas of the breast: an exploratory, hypothesis-generating study.
    Guerini-Rocco E; Hodi Z; Piscuoglio S; Ng CK; Rakha EA; Schultheis AM; Marchiò C; da Cruz Paula A; De Filippo MR; Martelotto LG; De Mattos-Arruda L; Edelweiss M; Jungbluth AA; Fusco N; Norton L; Weigelt B; Ellis IO; Reis-Filho JS
    J Pathol; 2015 Oct; 237(2):166-78. PubMed ID: 26011570
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Genomic alteration of MTAP/CDKN2A predicts sarcomatoid differentiation and poor prognosis and modulates response to immune checkpoint blockade in renal cell carcinoma.
    Xu W; Anwaier A; Liu W; Wei G; Su J; Tian X; Xia J; Qu Y; Zhao J; Zhang H; Ye D
    Front Immunol; 2022; 13():953721. PubMed ID: 35979371
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Novel therapeutic targets in salivary duct carcinoma uncovered by comprehensive molecular profiling.
    Gargano SM; Senarathne W; Feldman R; Florento E; Stafford P; Swensen J; Vranic S; Gatalica Z
    Cancer Med; 2019 Dec; 8(17):7322-7329. PubMed ID: 31609094
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Searching for mammary analogue [corrected] secretory carcinoma of salivary gland among its mimics.
    Pinto A; Nosé V; Rojas C; Fan YS; Gomez-Fernandez C
    Mod Pathol; 2014 Jan; 27(1):30-7. PubMed ID: 23807775
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Enhancer hijacking activates oncogenic transcription factor NR4A3 in acinic cell carcinomas of the salivary glands.
    Haller F; Bieg M; Will R; Körner C; Weichenhan D; Bott A; Ishaque N; Lutsik P; Moskalev EA; Mueller SK; Bähr M; Woerner A; Kaiser B; Scherl C; Haderlein M; Kleinheinz K; Fietkau R; Iro H; Eils R; Hartmann A; Plass C; Wiemann S; Agaimy A
    Nat Commun; 2019 Jan; 10(1):368. PubMed ID: 30664630
    [TBL] [Abstract][Full Text] [Related]  

  • 49. PD-L1 and PD-L2 Expression in Different Tumor Stages and Types of Malignant Salivary Gland Neoplasms: A Single-center Experience.
    Leaf Flag B; Cam I; Civriz AH; Tunce EB; Ozcan BC; Akyol YK; Deger HM; Vural C; Ozturk M
    Appl Immunohistochem Mol Morphol; 2024 Jun; ():. PubMed ID: 38847110
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Ten patients with high-grade transformation of acinic cell carcinomas: Expression profiling of β-catenin and cyclin D1 is useful.
    Yue LE; Samankan S; Liu X; Sharif KF; Everest S; Singh T; Dhorajiya P; Baik FM; Khorsandi A; Stevens TM; Brandwein-Weber M; Urken ML
    Pathol Res Pract; 2020 Feb; 216(2):152767. PubMed ID: 31812438
    [TBL] [Abstract][Full Text] [Related]  

  • 51. MR imaging features of mammary analogue secretory carcinoma and acinic cell carcinoma of the salivary gland: a preliminary report.
    Kashiwagi N; Nakatsuka SI; Murakami T; Enoki E; Yamamoto K; Nakanishi K; Chikugo T; Kurisu Y; Kimura M; Hyodo T; Tsukabe A; Kakigi T; Tomita Y; Ishii K; Narumi Y; Yagyu Y; Tomiyama N
    Dentomaxillofac Radiol; 2018 Jul; 47(5):20170218. PubMed ID: 29493279
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Expression of SOX10 in Salivary Gland Oncocytic Neoplasms: A Review and a Comparative Analysis with Other Immunohistochemical Markers.
    Schmitt AC; Cohen C; Siddiqui MT
    Acta Cytol; 2015; 59(5):384-90. PubMed ID: 26619208
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Evaluation of MTAP and p16 immunohistochemical deficiency as surrogate marker for CDKN2A/B homozygous deletion in gliomas.
    Maragkou T; Reinhard S; Jungo P; Pasquier B; Neuenschwander M; Schucht P; Vassella E; Hewer E
    Pathology; 2023 Jun; 55(4):466-477. PubMed ID: 37032198
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Prognostic value of PD-1 and PD-L1 expression in patients with metastatic clear cell renal cell carcinoma.
    Ueda K; Suekane S; Kurose H; Chikui K; Nakiri M; Nishihara K; Matsuo M; Kawahara A; Yano H; Igawa T
    Urol Oncol; 2018 Nov; 36(11):499.e9-499.e16. PubMed ID: 30131293
    [TBL] [Abstract][Full Text] [Related]  

  • 55. SOX10-positive salivary gland tumors: a growing list, including mammary analogue secretory carcinoma of the salivary gland, sialoblastoma, low-grade salivary duct carcinoma, basal cell adenoma/adenocarcinoma, and a subgroup of mucoepidermoid carcinoma.
    Hsieh MS; Lee YH; Chang YL
    Hum Pathol; 2016 Oct; 56():134-42. PubMed ID: 27327192
    [TBL] [Abstract][Full Text] [Related]  

  • 56. PD-L1 and p16 Expression in Penile Squamous Cell Carcinoma From an Endemic Region.
    De Bacco MW; Carvalhal GF; MacGregor B; Marçal JMB; Wagner MB; Sonpavde GP; Fay AP
    Clin Genitourin Cancer; 2020 Jun; 18(3):e254-e259. PubMed ID: 32139302
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Clinicopathological and Targeted Exome Gene Features of a Patient with Metastatic Acinic Cell Carcinoma of the Parotid Gland Harboring an ARID2 Nonsense Mutation and CDKN2A/B Deletion.
    Warner WA; Wong DJ; Palma-Diaz F; Shibuya TY; Momand J
    Case Rep Oncol Med; 2015; 2015():893694. PubMed ID: 26634163
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Prognostic value of programed death ligand-1 and ligand-2 co-expression in salivary gland carcinomas.
    Nakano T; Takizawa K; Uezato A; Taguchi K; Toh S; Masuda M
    Oral Oncol; 2019 Mar; 90():30-37. PubMed ID: 30846173
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Salivary Gland Secretory Carcinoma With High-Grade Transformation, CDKN2A/B Loss, Distant Metastasis, and Lack of Sustained Response to Crizotinib.
    Cipriani NA; Blair EA; Finkle J; Kraninger JL; Straus CM; Villaflor VM; Ginat DT
    Int J Surg Pathol; 2017 Oct; 25(7):613-618. PubMed ID: 28497708
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Aggressive morphologic variants of mantle cell lymphoma characterized with high genomic instability showing frequent chromothripsis, CDKN2A/B loss, and TP53 mutations: A multi-institutional study.
    Streich L; Sukhanova M; Lu X; Chen YH; Venkataraman G; Mathews S; Zhang S; Kelemen K; Segal J; Gao J; Gordon L; Chen Q; Behdad A
    Genes Chromosomes Cancer; 2020 Aug; 59(8):484-494. PubMed ID: 32277542
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.